Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Condensed Consolidated Statements Of Operations    
Revenues, net $ 65,274 $ 147,724
Operating expenses:    
Cost of implants and other costs 2,820 32,805
Research and development 145,965 59,006
Selling, general and administrative 1,394,665 591,422
Depreciation and amortization 2,194 3,446
Total operating expenses 1,545,644 686,679
Loss from operations (1,480,370) (538,955)
Other income (expenses):    
Interest expense, net (514,168) (462,791)
Grant income 224,059
Total other income (expenses) (290,109) (462,791)
Net loss before provision for income taxes (1,770,479) (1,001,746)
Income taxes
Net Loss (1,770,479) (1,001,746)
Non-controlling interest 28
NET LOSS ATTRIBUTIBLE TO BIOCORRX, INC. $ (1,704,479) $ (1,001,746)
Net loss per common share, basic and diluted $ (0.67) $ (0.41)
Weighted average number of common shares outstanding, basic and diluted 2,627,864 2,462,705